Navigation Links
Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
Date:10/30/2013

SAN FRANCISCO, Oct. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2013 on Thursday, November 7, 2013, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, December 9, 2013.

To access the conference call, follow these instructions:

Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)   
Passcode: 91919000 (Nektar Therapeutics is the host)

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar
Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigationa
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Inari Medical, Inc. announced ... B venture capital financing. The financing was led by ... Versant Ventures and US Venture Partners.  The round also ... "We are very pleased to complete this financing ... Bill Hoffman , who joined in February 2015 ...
(Date:6/30/2015)... , June 30, 2015  Avanir Pharmaceuticals, Inc. ... study showing that treatment with NUEDEXTA ® ... symptoms of pseudobulbar affect (PBA) in patients with ... a distressing condition characterized by sudden and uncontrollable ... neurologic diseases or brain injury. PRISM II is ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 /PRNewswire/ – ... ARYC) had an agreement to supply custom Arrayit blood ... private human DNA vault on earth. Vivos offers an ... provide virtually every man, woman and child on Earth, ... store their DNA. Arrayit blood cards allow the rapid ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7Small Cap IR - Empowering the Age of Genetic Enlightenment 2
... Sigma-Aldrich Corporation (NASDAQ: SIAL ) today announced ... ( www.safcglobal.com ), is introducing a novel CHOZN® GS-/- ... line. Designed for use in the production of biopharmaceuticals, ... commercially available glutamine synthetase (GS) knockout CHO cell line ...
...  The Eli Lilly and Company Foundation has committed US $30 ... in its fight against multidrug-resistant tuberculosis – a disease that ... each year. The announcement was made ahead of the opening ... Lille, France, later this week. Eli Lilly ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 2Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 3Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 4Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 5
(Date:6/30/2015)... ... 2015 , ... Tulika Ranjan, MD, a prominent neuro-oncologist from ... as Director of its Adult Neuro-Oncology program. , Dr. Ranjan’s clinical ... disease and the neurological complications of cancer. She has special expertise in ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... Joe Kennedy III (D-MA) and Danny Davis (D-IL) for writing to the Department ... investigation into the nation’s largest behavioral healthcare system, Universal Health Services (UHS).[1] CCHR ...
(Date:6/30/2015)... ... 2015 , ... The League for Innovation in the Community ... Predictive Analytics Reporting (PAR) Framework, and Susan Rundell Singer, Director of the Division ... at the 2015 STEMtech conference in Phoenix, Arizona, November 1-4. , Opening ...
(Date:6/30/2015)... ... June 30, 2015 , ... Amerec, a division of TyloHelo Inc, is pleased ... Daily is now approved by the Interior Design Continuing Education Council for 1 credit ... overview and explanation of what sauna, steam, and far-infrared saunas are, where they are ...
(Date:6/30/2015)... ... June 30, 2015 , ... People ... face in the aftermath of a near-death experience (NDE) – and also want ... providing adequate treatment options – are invited to visit https://zoom.us/webinar/register/f4a12556fe7c03f5dc2040ba88984b7b ...
Breaking Medicine News(10 mins):Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 2Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 2Health News:League for Innovation Announces Distinguished Keynote Presenters for STEMtech Conference 3Health News:Amerec’s Steam and Sauna Continuing Education Course Now Approved for Interior Design Credit 2Health News:IANDS Sponsors No-Cost Webinar on July 1/15 at 11CST Featuring Combat Soldier Who Survived Near-Death Experience 2Health News:IANDS Sponsors No-Cost Webinar on July 1/15 at 11CST Featuring Combat Soldier Who Survived Near-Death Experience 3
... naloxone saves heroin addicts from overdose and it is ... for life saving emergencies, according to doctors at the ... given by doctors, during emergency resuscitation following narcotic overdose. ... training in emergency resuscitation with the aid of the ...
... Endodontists in New Orleans, Louisiana, began with a warning from ... that all toothache need not have dental origins and that ... early warning for more important problems. Especially in the third ... due importance from the masses. So much so that patients ...
... which is now the third most affected country by the ... every five South African is HIV positive. If this isn’t ... controversy, as it refused a huge consignment of one million ... U.S. Dollars. ,Earlier last year the South African president ...
... in the United States of America has zeroed in on ... gene has been isolated which is said to be the ... years. However the most widely held explanation for this is ... physical activity.,Also scientists were keen on the role of estrogen, ...
... of America, says that children suffer the most when parents ... avoid a divorce for the sake of children, instead of ... to the kids, the authors of the study say.,Dr. Allan ... in University Park conducted the exhaustive study over a seventeen-year ...
... the group of scientists asking for more funding into stem cell ... President George W. Bush asking him not to block stem cell ... reaching a feverish pitch with both sides slamming each other on ... oppose it call the research as immoral, those supporting it call ...
Cached Medicine News:
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Short 19 mm. Overall length: 3.9 inches....
Size 2 dilator. Stainless steel. Round knurled handle with polished finish. Overall length: 4 inches....
Double ended dilator probes with gentle curve. Stainless steel. Round knurled handle with polished finish. Overall length: 5.3 inches....
Medicine Products: